The result of orlistat in people with hepatic and/or renal impairment hasn't been researched (see segment 4.4). having said that, as orlistat is minimally absorbed, no dose adjustment is critical in people today with hepatic and/or renal impairment. Adverse reactions to orlistat are mainly gastrointestinal in mother nature and linked to the pharma